<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23339">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01856413</url>
  </required_header>
  <id_info>
    <org_study_id>BT 987</org_study_id>
    <secondary_id>2012-002516-51</secondary_id>
    <nct_id>NCT01856413</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Zutectra in Patients Who Recently Received a Liver Transplant</brief_title>
  <acronym>ZEUS</acronym>
  <official_title>An Open, Prospective, Single Arm Study Investigating Efficacy and Safety of Human Hepatitis B Immunoglobulin Zutectra in Liver Transplanted Patients - the ZEUS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotest</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotest</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who receive liver transplantation for hepatitis B virus (HBV) induced liver failure
      require longterm therapy to prevent HBV reinfection of the transplanted liver. The approved
      preventative treatment is a combination of antihepatitis B immunoglobulin (HBIg) and oral
      antiviral medication. In the first 6 months after liver transplantation, patients receive
      treatment with intravenous HBIg to maintain blood antihepatitis B (antiHBs)antibody
      concentrations above 100 IU/L, the level considered safe for preventing hepatitis B
      reinfection.

      Zutectra is an HBIg preparation for subcutaneous injection that is approved in the EU for
      the 'prevention of HBV reinfection in HBV DNA negative patients ≥ 6 months after liver
      transplantation for hepatitis B induced liver failure'. The purpose of this study is to show
      that earlier subcutaneous HBIg treatment with Zutectra after liver transplantation can
      prevent hepatitis B reinfection.

      Treatment with subcutaneous HBIg (Zutectra) at home is manageable for the majority of
      patients and is more convenient for patients compared to intravenous treatment that must
      take place in the hospital setting.

      Sixty patients will take part in the study at approximately 19 centres in UK, France, Italy
      and Spain. Patients who are eligible for the study will receive treatment with Zutectra for
      24 weeks.

      During the study, the safety and effectiveness of Zutectra will be assessed by checking for
      symptoms of hepatitis B related infection, as well as monitoring blood levels of antiHBs
      antibodies and hepatitis B surface antigen (HBsAg).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Trough levels of serum anti-HBs antibody concentrations</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B related re-infections</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of all patients with hepatitis B related infections will be assessed by monitoring of clinical signs, liver function and measurement of HBsAg and HBV-DNA.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of adverse events will be documented including safety laboratory parameters reported as AEs.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Zutectra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zutectra</intervention_name>
    <description>Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.</description>
    <arm_group_label>Zutectra</arm_group_label>
    <other_name>Human hepatitis B Immunoglobulin</other_name>
    <other_name>HBIg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained prior to orthotopic liver transplantation (OLT) -
             not more than 3 months before OLT

          -  Historical evidence within the last 4 weeks that HBV-DNA is undetectable at time
             point of signature of Informed Consent

          -  Male and female patients (age 18-75 years)

          -  Patients with the diagnosis of liver failure with hepatitis B infection

          -  Patients undergoing liver transplantation or re-transplantation

          -  HBsAg negative on day 7 or on day 14 after OLT

          -  HBV-DNA undetectable at OLT

          -  Serum HBs antibody concentration on day 7 or on day 14 after OLT ≥ 400 IU/l

          -  Stable patient in a condition which in the opinion of the investigator would permit
             safe participation in the study

          -  Willingness to fill out patient diary

        Exclusion Criteria:

          -  Re-transplantation due to viral recurrence

          -  Positive HIV or HCV test at time of transplantation

          -  HBV-DNA positive at OLT

          -  Patients having received organs from HBsAg positive donors

          -  Pregnancy or unreliable contraceptive measures or lactation period (females only)

          -  Known intolerance to immunoglobulins or comparable substances (e.g. vaccination
             reaction)

          -  Known intolerance to proteins of human origin

          -  Participation in another interventional clinical trial within 90 days before entering
             the study or during the study and/or previous participation in this study (except
             screening failures)

          -  Suspicion of drug and/or alcohol abuse

          -  Inability or lacking motivation to participate in the study

          -  Employee or direct relative of an employee of the CRO, the study site, or Biotest
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Samuel, Professeur</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Paul Brousse, Centre Hepato-Biliaire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Orsola Hospital</name>
      <address>
        <city>Bologna</city>
        <zip>40139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Brotzu</name>
      <address>
        <city>Cagliari</city>
        <zip>CA 09135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedialera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Molinette Hospital</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>May 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention</keyword>
  <keyword>Hepatitis B virus re-infection</keyword>
  <keyword>HBV-DNA negative</keyword>
  <keyword>Liver transplantation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
